We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.40 | 1.60 | 1.55 | 1.45 | 1.50 | 960,461 | 16:02:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -4.29 | 2.03M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/9/2020 13:17 | Newtoaim is here. This is definitely gonna pop. | hodhasharon | |
03/9/2020 13:15 | So your posting 1 year old articles to get the pump going | newtoaim | |
03/9/2020 13:11 | Its filtering out... herd about to arrive... boom time coming | easwarareddy | |
03/9/2020 12:54 | An article by Tom Howard in the Daily Mail on Physiomics last year at 3.7p Great call ! He now writes for The Times SMALL CAP SHARE IDEAS: Virtual tumour software Physiomics starting to catch cancer world's attention | the stigologist | |
03/9/2020 12:42 | Still here though with opinions,wether you like it or not. | albert3591 | |
03/9/2020 12:37 | Probably back to level eod. | albert3591 | |
03/9/2020 12:33 | You two really are clueless. | hodhasharon | |
03/9/2020 12:31 | Seems like that jusjus | albert3591 | |
03/9/2020 12:28 | 3 x 100k (x 2) now looking like a classic p&d for a quick £1.5k each! | jusjusjus | |
03/9/2020 12:00 | More so than at any time in the past this chart set up looks primed for a break to the upside... the recent spikes are just 'pathfinders' or feelers as to where the market believes this can go I think there is scope for gamechanging news on several fronts | the stigologist | |
03/9/2020 11:53 | What sort of upfront licence fee could VAL/PYC expect if they licence VAL201 for wider Phase II after upcoming Phase I/II results ? These are 2011-16 numbers. You can bet we could expect more now. All depends on exact detail of the Phase I/II results. | the stigologist | |
03/9/2020 11:42 | series of 100k buys appear to have kicked this off, just like on VAL! | jusjusjus | |
03/9/2020 11:25 | Those sells hardly moved price. Large buys being filled | stoneme | |
03/9/2020 11:21 | what an investment combo (which I happened across by following some of you more savvy investors) - PYC & VAL | jusjusjus | |
03/9/2020 11:20 | Jumping into auction. | hodhasharon | |
03/9/2020 11:19 | if we breakout chart says 12p first port of call! | jusjusjus | |
03/9/2020 11:16 | davevt and albert are probably just out on a date. | hodhasharon | |
03/9/2020 11:09 | I hope all new investors have read and absorbed the 100p Manifesto? | hodhasharon | |
03/9/2020 10:47 | VAL storming higher today in anticipation of Phase I/II Prostate Cancer clinical trial results on VAL201 due in September (so any day now) PYC Physiomics have a FREE carried LICENCE SHARE on ANY income from VAL201 ANY licensing income - so if VAL licence VAL201 to a Big Pharma they'll have to share ANY income (Upfronts, Licence milestones, Royalties etc with Physiomics) Will be TOTALLY TRANSFORMATIONAL for PYC (Mkt Cap c.£7m at 7p) | the stigologist | |
03/9/2020 10:30 | Sells at 7 on the nose, just as predicted. Get ready for the 6s... | davevt | |
03/9/2020 09:47 | I'm sure some Val profits will be making there way here! | tonytony4 | |
03/9/2020 09:40 | Surprised no derampers today I'm sure they will make there entrance. In the mean time a little top-up won't harm! | tonytony4 | |
03/9/2020 09:37 | Lol, at the most recent post on LSe, guy is posting links about the wrong Merck, and claims pyc is at the 'forefront of ai'. No dude, it couldn't actually be any further behind, in fact I don't think you could find a company that does any less. | davevt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions